Suggested remit: To appraise the clinical and cost effectiveness of osimertinib within its marketing authorisation as maintenance treatment of EGFR mutation-positive locally advanced or unresectable non-small-cell lung cancer (NSCLC) which has not progressed after platinum based chemoradiation.
 
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process STA Standard
ID number 6223

Provisional Schedule

Committee meeting 12 June 2025
Expected publication 20 August 2025

Project Team

Project lead Leena Issa

Email enquiries

External Assessment Group Liverpool Reviews and Implementation Group, University of Liverpool

Stakeholders

Companies sponsors AstraZeneca (osimertinib)
Others Department of Health and Social Care
  NHS England
Patient carer groups Asthma and Lung UK
  Black Health Agency for Equality
  Cancer Black Care
  Cancer Equality
  EGFR Positive
  Helen Rollason Cancer Charity
  Independent Cancer Patients Voice
  Macmillan Cancer Support
  Maggie’s Centres
  Marie Curie
  Oncogene Cancer Research
  Oncogene-Driven Lung Cancer Patient Alliance UK
  Roy Castle Lung Cancer Foundation
  South Asian Health Foundation
  Specialised Healthcare Alliance
  Tenovus Cancer Care
  UK Lung Cancer Coalition
Professional groups Association of Anaesthetists
  Association of Cancer Physicians
  Association of Respiratory Nurse Specialists
  Association of Surgeons of Great Britain and Ireland
  British Geriatrics Society
  British Institute of Radiology
  British Oncology Pharmacy Association
  British Psychosocial Oncology Society
  British Society of Interventional Radiology
  British Thoracic Oncology Group
  British Thoracic Society
  British Transplantation Society
  Cancer Research UK
  Lung Cancer and Mesothelioma Clinical Expert Group
  Lung Cancer Nursing UK
  National Heart and Lung Institute
  NHS Blood and Transplant
  Primary Care Respiratory Society
  Royal College of Anaesthetists
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Radiologists
  Royal College of Surgeons
  Royal Pharmaceutical Society
  Royal Society of Medicine
  Society and College of Radiographers
  UK Clinical Pharmacy Association
  UK Oncology Nursing Society
Associated public health groups Public Health Wales
  UK Health Security Agency
Comparator companies AstraZeneca (durvalumab)
General commentators All Wales Therapeutics and Toxicology Centre
  Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health – Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  NHS Confederation
  Scottish Medicines Consortium
  Welsh Government
  Welsh Health Specialised Services Committee
Relevant research groups Cochrane Lung Cancer Group
  Cochrane UK
  Genomics England
  Institute of Cancer Research
  MRC Clinical Trials Unit
  National Institute for Health Research

Timeline

Key events during the development of the guidance:

Date Update
30 October 2024 Invitation to participate
10 July 2024 - 07 August 2024 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6223
10 July 2024 In progress. Scoping commencing
14 March 2024 Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during late October 2024 when we will write to you about how you can get involved.
26 January 2024 Please note that following on from advice received from the company, further information regarding the timelines for this appraisal will be available in due course. In the meantime, NICE will continue to monitor the situation and will provide an update as and when the situation changes.
31 July 2023 Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during mid-July 2024.
16 December 2022 Awaiting development. Status change linked to Topic Selection Decision being set to Selected
28 November 2022 Topic selection

For further information on our processes and methods, please see our CHTE processes and methods manual